GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population

International Journal of Cancer

Volumn 110, Issue 4, 2004, Pages 598-604

  Hung, Rayjean J ^a,b   Boffetta, Paolo ^a   Brennan, Paul ^a   Malaveille, Christian ^a   Hautefeuille, Agnès ^a   Donato, Francesco ^c   Gelatti, Umberto ^c   Spaliviero, Massimiliano ^c   Placidi, Donatella ^c   Carta, Angela ^c   Di Carlo, Antonio Scotto ^c   Porru, Stefano ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Aromatic amines; Bladder cancer; CYP1B1; Genetic polymorphism; GSTM1; GSTP1; GSTT1; NAT1; NAT2; PAH; SULT1A1

Indexed keywords

ACYLTRANSFERASE; ARGININE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1B1; GLUTATHIONE TRANSFERASE; HISTIDINE; ISOENZYME; N ACETYLTRANSFERASE 1; POLYCYCLIC AROMATIC HYDROCARBON; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OCCUPATIONAL EXPOSURE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; ARYLSULFOTRANSFERASE; ENVIRONMENTAL EXPOSURE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MIDDLE AGED; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 2442709151     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20157     Document Type: Article

References (61)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. (1.0). IARC Cancer Base No. 5. Lyon: IARC, 2001.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Lyon: IARC, 2002.
3. Porru S, Aulenti V, Donato F, Boffetta P, Fazioli R, Cosciani CS, Alessio L. Bladder cancer and occupation: a case-control study in Northern Italy. Occup Environ Med 1996;53:6-10.
4. Kogevinas M, Trichopoulos D. Urinary bladder cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Textbook of cancer epidemiology. New York: Oxford University Press, 2002. 446-66.
5. Strange RC, Fryer AA. The glutathione s-transferases: influence of polymorphism on cancer susceptibility. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P, eds. Metabolic polymorphisms and susceptibility to cancer. Lyon: IARC, 1999. 231-49.
6. Eaton DL, Bammler TK. Concise review of the glutathione s-transferases and their significance to toxicology. Toxicol Sci 1999;49:156-64.
7. Landi S. Mammalian class θ GST and differential susceptibility to carcinogens: a review. Mutat Res 2000;463:247-83.
8. Ketterer B. Glutathione S-Transferase polymorphism and susceptibility to cancer. In: Mendelsohn ML, Mohr LC, Peeters JP, eds. Biomarkers: medical and workplace applications. Washington: National Academy of Sciences, 1998. 211-26.
9. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J, Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione s-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997;272:10004-12.
10. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275-80.
11. Hu X, O'Donnell R, Srivastava SK, Xia H, Zimniak P, Nanduri B, Bleicher RJ, Awasthi S, Awasthi YC, Ji X, Singh SV. Active site architecture of polymorphic forms of human glutathione s-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7β,8α-dihydroxy-9α,10α-ox y-7,8,9,10-tetrahydrobenzo(a)pyrene. Biochem Biophys Res Commun 1997;235: 424-8.
12. Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Mannervik B, Jernstrom B. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998;19:433-6.
13. d'Errico A, Malats N, Vineis P, Boffetta P. Review of studies of selected metabolic polymorphisms and cancer. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P, eds. Metabolic polymorphisms and susceptibility to cancer. Lyon: IARC, 1999. 323-93.
14. Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, Boffetta P, Vineis P, Autrup H, Bell DA, Branch RA, Brockmoller J, et al. Pooled analysis and meta-analysis of glutathione s-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 2002;156: 95-109.
15. Johns LE, Houlston RS. Glutathione s-transferase mul (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis 2000;15: 399-404.
16. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM. Glutathione s-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 1996;71: 123-6.
17. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione s-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25.
18. Giannakopoulos X, Charalabopoulos K, Baltogiannis D, Chatzikiriakidou A, Alamanos Y, Georgiou I, Evangelou A, Agnantis N, Sofikitis N. The role of N-acetyltransferase-2 and glutathione s-transferase on the risk and aggressiveness of bladder cancer. Anticancer Res 2002;22:3801-4.
19. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, Tez M, Cetinkaya M, Ozcelik T. Polymorphisms of glutathione s-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol 2001;75:459-64.
20. Lee SJ, Cho SH, Park SK, Kim SW, Park MS, Choi HY, Choi JY, Lee SY, Im HJ, Kim JY, Yoon KJ, Choi H, et al. Combined effect of glutathiones-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 2002;177:173-9.
21. Kim WJ, Kim H, Kim CH, Lee MS, Oh BR, Lee HM, Katoh T. GSTT1-null genotype is a protective factor against bladder cancer. Urology 2002;60:913-8.
22. Ma QW, Lin GF, Chen JG, Shen JH. Polymorphism of glutathione s-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci 2002;15:253-60.
23. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione s-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-4.
24. To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, Carrasco JL, Ramon J, Corbella J. Genetic polymorphism of glutathione s-transferase P1 gene and lung cancer risk. Cancer Causes Control 1999;10:65-70.
25. Jourenkova-Mironova N, Wikman H, Bouchardy C, Voho A, Dayer P, Benhamou S, Hirvonen A. Role of glutathione s-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenetics 1998;8:495-502.
26. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione s-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-4.
27. Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K, Itoh H, Matsumoto T, Kawamoto T, Bell DA. Human glutathione s-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics 1999;9:165-9.
28. Steinhoff C, Franke KH, Golka K, Thier R, Romer HC, Rotzel C, Ackermann R, Schulz WA. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 2000;74:521-6.
29. Saarikoski ST, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998;77:516-21.
30. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM, Au WW. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 1998;22:129-38.
31. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
32. Hein D. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.
33. Hirvonen A, Polymorphic NATs and cancer predisposition, In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P, eds. Metabolic polymorphisms and susceptibility to cancer. Lyon: IARC, 1999. 251-70.
34. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmoller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000;9:461-7.
35. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000;10:115-22.
36. Cascorbi I, Roots I, Brockmoller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001;61:5051-6.
37. Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY, Chen CJ. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 1999;81:537-41.
38. Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, Coughtrie MW, Andrae U, Falany CN, Meinl W. Sulfotransferases: genetics and role in toxicology. Toxicol Lett 2000;112-113:341-8.
39. Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione s-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 1998;154:47-85.
40. Engelke CE, Meinl W, Boeing H, Glatt H. Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. Pharmacogenetics 2000;10:163-9.
41. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM, Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997;239:298-304.
42. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K, Catalytic properties of polymorphic human cytochrome P450 1B1 variants, Carcinogenesis 1999;20:1607-13.
43. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038-41.
44. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-44.
45. Porru S, Placidi D, Carta A, Gelatti U, Ribero ML, Tagger A, Boffetta P, Donato F. Primary liver cancer and occupation in men: a case-control study in a high-incidence area in Northern Italy. Int J Cancer 2001;94:878-83.
46. Fryer AA, Zhao L, Alldersea J, Pearson WR, Strange RC. Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione s-transferase, GSTM1 locus. Biochem J 1993;295:313-5.
47. Bartsch H, Malaveille C, Lowenfels AB, Maisonneuve P, Hautefeuille A, Boyle P. Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. Eur J Cancer Prev 1998;7: 215-23.
48. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione s-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6.
49. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14: 1689-92.
50. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G, Vineis P. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1998;7:341-6.
51. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995;55:3537-42.
52. Deitz AC, Doll MA, Hein DW. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles, Anal Biochem 1997;253:219-24.
53. Ozawa S, Tang YM, Yamazoe Y, Kato R, Lang NP, Kadlubar FF. Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact 1998;109: 237-48.
54. Perera FP. Environment and cancer: who are susceptible? Science 1997;278:1068-73.
55. Yu MC, Ross RK, Chan KK, Henderson BE, Skipper PL, Tannenbaum SR, Coetzee GA. Glutathione s-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995; 4:861-64.
56. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, Golka K, Okkels H, Risch A, Rothman N, Sim E, Taioli E, Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001;10:1249-52.
57. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996;15:273-80.
58. Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N, Wu X. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 2002;35:137-42.
59. Peng CT, Chen JC, Yeh KT, Wang YF, Hou MF, Lee TP, Shih MC, Chang JY, Chang JG. The relationship among the polymorphisms of SULT1A1, 1A2 and different types of cancers in Taiwanese. Int J Mol Med 2003;11:85-9.
60. Wu MT, Wang YT, Ho CK, Wu DC, Lee YC, Hsu HK, Kao EL, Lee JM. SULT1A1 polymorphism and esophageal cancer in males. Int J Cancer 2003;103:101-4.
61. Ozawa S, Katoh T, Inatomi H, Imai H, Kuroda Y, Ichiba M, Ohno Y. Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer 2002;102:418-21.